Cigna said on Wednesday it was launching an add-on to pharmacy benefit management plans in which patients could pay no more ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...